• <sub id="naktq"><address id="naktq"><nobr id="naktq"></nobr></address></sub>
    <em id="naktq"></em>

      <sub id="naktq"><td id="naktq"><nobr id="naktq"></nobr></td></sub>

      1. <form id="naktq"><th id="naktq"><track id="naktq"></track></th></form>

        <wbr id="naktq"></wbr>

          <big id="naktq"><td id="naktq"></td></big><u id="naktq"><ins id="naktq"></ins></u>
          <form id="naktq"></form>

          A POWERFUL RESEARCH AND
          DEVELOPMENT ENGINE

          Our unique ability to repeatedly and consistently translate science into medicine has led to a robust pipeline of clinical-stage medicines, all of which were discovered in our laboratories. Our investigational treatments target allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

          Interact with the Regeneron Pipeline

          Select Therapeutic Area(s):
          Select Phase(s):
          Select Collaborator(s):

          Displaying item(s)

          Clear Filters

          Phase 1 trials Phase 1 trials
          • CEMIPLIMAB*
            PD-1 Antibody Cancer
          • REGN3767
            LAG-3 Antibody Cancer
          • REGN1979
            CD20xCD3 Antibody Cancer
          • REGN4018*
            MUC16xCD3 Antibody Cancer
          • REGN5093
            METxMET Antibody Cancer
          • REGN5458*
            BCMAxCD3 Antibody Cancer
          • REGN5459*
            BCMAxCD3 Antibody Cancer
          • REGN5678
            PSMAxCD28 Antibody Cancer
          • REGN5713-5714-5715
            Betv1 Antibody Birch Allergy
          Phase 2 trials Phase 2 trials
          • AFLIBERCEPT
            VEGF Trap High-dose for wet age-related macular degeneration (AMD)
          • CEMIPLIMAB*
            PD-1 Antibody Basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (CSCC)
          • REGN1979
            CD20xCD3 Antibody Relapsed/refractory follicular lymphoma, non-Hodgkin lymphomas, diffuse large B-cell lymphoma
          • DUPILUMAB*
            IL-4R Antibody Grass allergy, peanut allergy
          • SARILUMAB*
            IL-6R Antibody Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis
          • REGN1908-1909
            Fel d 1 Antibody Cat allergy
          • REGN3500*
            IL-33 Antibody Asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis
          • REGN5069
            GFRα3 Antibody Osteoarthritis knee pain
          • REGN4461
            LEPR Antibody Generalized lipodystrophy
          • GARETOSMAB
            Activin A Antibody Fibrodysplasia Ossificans Progressiva (FOP)
          • EVINACUMAB
            ANGPTL-3 Antibody Refractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemia
          • POZELIMAB
            C5 Antibody Paroxysmal nocturnal hemoglobinuria
          Phase 3 trials Phase 3 trials
          • AFLIBERCEPT
            VEGF Trap Retinopathy of Prematurity (ROP)
          • ALIROCUMAB*
            PCSK9 Antibody Homozygous familial hypercholesterolemia (HoFH) in adults and pediatrics, heterozygous familial hypercholesterolemia in pediatrics
          • CEMIPLIMAB*
            PD-1 Antibody Non-small cell lung cancer (NSCLC), cervical cancer, cutaneous squamous cell carcinoma (CSCC) (adjuvant)
          • REGN-EB3
            Ebola Virus Antibody Ebola virus infection
          • DUPILUMAB*
            IL-4R Antibody Atopic dermatitis in pediatrics, asthma in pediatrics, eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD), prurigo nodularis, bullous pemphigoid, chronic spontaneous urticaria
          • SARILUMAB*
            IL-6R Antibody Polymyalgia rheumatica, giant cell arteritis
          • EVINACUMAB
            ANGPTL-3 Antibody Homozygous familial hypercholesterolemia (HoFH)
          • FASINUMAB?
            NGF Antibody Chronic pain from osteoarthritis of the knee or hip

          No results found, please adjust your filter selection and try again.

          * In collaboration with Sanofi

          ? In collaboration with Teva and Mitsubishi Tanabe

          This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

          caoponrn免费公开视频